Merck Serono   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Darmstadt Germany (2006)

Organization Overview

First Clinical Trial
2006
NCT00489528
First Marketed Drug
2006
clomifene (clomid)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ayudas Merck Serono de Investigación 2012 | Beijing Merck Pharmaceutical Consulting Ltd., China | EMD Serono | EMD SERONO | EMD Serono a division of EMD Canada Inc. | EMD Serono Canada Inc. | EMD SERONO INC | EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany | EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany | EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany | EMD Serono Inc., an Affiliate of Merck KGaA, Darmstadt, Germany | EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany | EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany | EMD Serono, Inc., Billerica MA, a subsidiary of Merck KGaA, Darmstadt, Germany | EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany | EMD Serono Research & Development Institute, Inc. | EMD Serono Research & Development Institute, Inc, a business of Merck KGaA, Darmstadt, Germany | EMD Serono Research & Development Institute, Inc. a business of Merck KGaA, Darmstadt, Germany | EMD Serono Research & Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany | EMD Serono Research & Development Institute, Inc, an affiliate of MerckKGaA, Darmstadt, Germany | EMD Serono Research & Development Institute, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany | EMD Serono Research & Development Institute, Inc., the biopharmaceutical division of Merck KGaA, Darmstadt, Germany | Merck Serono, a division of Merck KGaA, Darmstadt, Germany | Merck Serono Australia Pty Ltd | Merck Serono Austria a division of Merck Gesellschaft mbH, Austria, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono Co.,Ltd, an Affilate of Merck Serono, Darmstadt, Germany | Merck Serono Co., Ltd., Beijing | Merck Serono. Co., Ltd, Beijing, China | Merck Serono Co., Ltd., China | Merck Serono Co., Ltd., Japan | Merck Serono Europe Limited, an affiliate of MerckKGaA, Darmstadt, Germany | Merck Serono Europe Ltd | Merck Serono GmbH, Germany | Merck Serono International SA | Merck Serono International S.A., an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono International SA, an affiliate of Merck KGaA Darmstadt, Germany | Merck Serono International, S.A., an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono Limited, UK | Merck Serono Middle East FZ LLC | Merck Serono Norway | MerckSerono Pharmaceuticals | Merck Serono SA | Merck Serono S.A., a business of Merck KGaA, Darmstadt, Germany | Merck Serono S.A., an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono SA, an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono S.A., Geneva | Merck Serono SA - Geneva | Merck Serono S.A. - Geneva, an affiliate of MerckKGaA, Darmstadt, Germany | Merck Serono SA - Geneva, an affiliate of Merck KGaA Darmstadt, Germany | Merck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany | Merck Serono S.A.S, France | Merck Serono Spain | Merck Serono, Spain | Merck Serono S.P.A., Italy | Merck Serono Vietnam | Merck Services U.K. Ltd, UK

Active Ingredients

Marketed Drugs (12)

Key: Merck Serono (3) Acquired (9)

avelumab (bavencio) (2017)

cetrorelix (cetrotide) (2000)

cladribine (leustatin) (2019)

clomifene (clomid) (1982)

follitropin alfa (Gonal-F) (1997)

lutropin alpha (luveris) (2004)

metformin (glucophage) (1995)

mitoxantrone (novantrone) (1987 NDA)

recombinant human choriogonadotropin alfa (Ovidrel) (2000)

sermorelin (geref) (1990 NDA)

somatropin (protropin) (1996)

tepotinib (Tepmetko) (2021)

Drugs in Phase 4 Trials (29)

Key: Merck Serono (4) Acquired (25)

atenolol (tenormin) (2 trials)

bisoprolol (zebeta) (10 trials)

cetrorelix (cetrotide) (4 trials)

chlorquinaldol (1 trial)

cladribine (leustatin) (14 trials)

cyclosporine (sandimmune) (1 trial)

dydrogesterone (gynorest) (1 trial)

efalizumab (Raptiva) (7 trials)

follitropin alfa (Gonal-F) (33 trials)

gabapentin (neurontin) (2 trials)

ganirelix (2 trials)

glatiramer acetate (copaxone) (2 trials)

gonadorelin (factrel) (2 trials)

interferon beta-1b (betaseron) (27 trials)

lutropin alpha (luveris) (18 trials)

menopausal gonadotropin (1 trial)

metoprolol (lopressor) (1 trial)

metronidazole (flagyl) (1 trial)

mitoxantrone (novantrone) (1 trial)

naltrexone (revia) (5 trials)

nicorandil (3 trials)

prednisone (meticorten) (3 trials)

pregabalin (lyrica) (1 trial)

progesterone (progestasert) (7 trials)

promestriene (1 trial)

recombinant human choriogonadotropin alfa (Ovidrel) (17 trials)

sapropterin (kuvan) (4 trials)

sitagliptin (januvia) (6 trials)

somatropin (protropin) (25 trials)

Drugs in Phase 3 Trials (53)

Key: Merck Serono (7) Acquired (46)

acamprosate (campral) (1 trial)

adalimumab (humira) (4 trials)

amlodipine (norvasc) (2 trials)

anastrozole (arimidex) (2 trials)

atacicept (13 trials)

avelumab (bavencio) (62 trials)

azacitidine (vidaza) (1 trial)

bacille calmette-guerin (2 trials)

bendamustine (treanda) (1 trial)

bevacizumab (avastin) (6 trials)

binimetinib (mektovi) (3 trials)

bintrafusp alfa (21 trials)

capecitabine (xeloda) (7 trials)

carboplatin (paraplatin) (12 trials)

cetuximab (erbitux) (54 trials)

cilengitide (11 trials)

cisplatin (platinol) (25 trials)

cmv-specific t-cells (1 trial)

cyclophosphamide (cytoxan) (12 trials)

docetaxel (taxotere) (3 trials)

encorafenib (braftovi) (5 trials)

evobrutinib (17 trials)

evofosfamide (7 trials)

fluorouracil (efudex) (24 trials)

follitropin beta (Follistim) (1 trial)

gemcitabine (gemzar) (16 trials)

irinotecan (Camptosar) (16 trials)

lactobacillus casei (1 trial)

leucovorin (17 trials)

metformin (glucophage) (11 trials)

mitumomab (1 trial)

mycophenolate (CellCept) (2 trials)

niacin (2 trials)

omega-3 fatty acids (Omacor) (1 trial)

oxaliplatin (eloxatin) (11 trials)

paclitaxel (taxol) (11 trials)

peginterferon beta-1a (Plegridy) (7 trials)

pemetrexed (alimta) (7 trials)

phenylalanine (1 trial)

praziquantel (biltricide) (9 trials)

ribavirin (virazole) (1 trial)

rituximab (rituxan) (2 trials)

safinamide (xadago) (8 trials)

sarizotan (4 trials)

sodium chloride (4 trials)

tecemotide (11 trials)

temozolomide (temodar) (4 trials)

teriflunomide (aubagio) (2 trials)

tumor necrosis factor receptor type i, p55 soluble fragment (1 trial)

urinary human chorionic gonadotrophin (1 trial)

urofollitropin (Metrodin) (1 trial)

utomilumab (1 trial)

vinorelbine (navelbine) (2 trials)

Drugs in Phase 2 Trials (79)

Key: Merck Serono (16) Acquired (63)

13c-pyruvate (2 trials)

89zirconium-m7824 (1 trial)

abiraterone (zytiga) (1 trial)

abituzumab (6 trials)

afatinib (gilotrif) (1 trial)

arx201 (1 trial)

as900672 (2 trials)

atx-ms-1467 (1 trial)

avb-s6-500 (1 trial)

bempegaldesleukin (1 trial)

berzosertib (2 trials)

calcium carbonate (1 trial)

ceralifimod (1 trial)

clomifene (clomid) (1 trial)

compound 121564 (1 trial)

compound 2055269 (1 trial)

compound 451238 (1 trial)

curcumin (1 trial)

dacarbazine (dtic-dome) (1 trial)

d-aspartate (1 trial)

dimethyl fumarate (tecfidera) (1 trial)

Domatinostat (2 trials)

doxorubicin (Doxil) (3 trials)

durvalumab (imfinzi) (1 trial)

emd 1201081 (4 trials)

emd 273063 (1 trial)

emd 521873 (3 trials)

emfilermin (2 trials)

entinostat (1 trial)

enzalutamide (xtandi) (2 trials)

epirubicin (ellence) (2 trials)

estrogen (1 trial)

etoposide (vepesid) (1 trial)

folic acid (1 trial)

gefitinib (iressa) (2 trials)

gen-001 (2 trials)

gimeracil (1 trial)

goserelin (zoladex) (1 trial)

levodopa (larodopa) (1 trial)

levoleucovorin (fusilev) (1 trial)

m3814 (4 trials)

m4344 (1 trial)

m5049 (6 trials)

m6223 (2 trials)

m6620 (5 trials)

m7583 (2 trials)

matuzumab (4 trials)

mcpyv tag-specific polyclonal autologous cd8-positive t cells (1 trial)

methotrexate (2 trials)

methylprednisolone (medrol) (1 trial)

minocycline (minocin) (1 trial)

niraparib (zejula) (1 trial)

nktr-255 (1 trial)

osimertinib (tagrisso) (1 trial)

oteracil (1 trial)

pembrolizumab (keytruda) (2 trials)

pimasertib (12 trials)

plovamer (1 trial)

pt-112 (1 trial)

regorafenib (stivarga) (1 trial)

s-1 (1 trial)

sacituzumab govitecan (Trodelvy) (1 trial)

sorafenib (nexavar) (1 trial)

sprifermin (5 trials)

talazoparib (talzenna) (1 trial)

tegafur (2 trials)

tepotinib (Tepmetko) (19 trials)

tg4001 (1 trial)

tomivosertib (1 trial)

topotecan (hycamtin) (2 trials)

trastuzumab (herceptin) (2 trials)

trx518 (1 trial)

tucotuzumab celmoleukin (3 trials)

uracil (1 trial)

valproic acid (depakene) (1 trial)

vitamin d3 (2 trials)

vx15/2503 (1 trial)

vxm01 (1 trial)

xl765 (2 trials)

Drugs in Phase 1 Trials (51)

Key: Merck Serono (5) Acquired (46)

as-703988 (1 trial)

cabozantinib (cometriq) (1 trial)

capravirine (1 trial)

carbamazepine (tegretol) (2 trials)

cenisertib (3 trials)

ciprofloxacin (cipro) (1 trial)

dabigatran (pradaxa) (1 trial)

debio 1143 (1 trial)

dexamethasone (1 trial)

diclofenac (voltaren) (1 trial)

digoxin (lanoxin) (1 trial)

emd-1204831 (1 trial)

emd 640744 (1 trial)

eribulin (halaven) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

Filgrastim (neupogen) (2 trials)

futuximab (2 trials)

gliclazide (2 trials)

hu5f9-g4 (1 trial)

interleukin-12 (1 trial)

itraconazole (sporanox) (1 trial)

lenvatinib (lenvima) (1 trial)

levonorgestrel (1 trial)

levothyroxine (Synthroid) (3 trials)

m1069 (1 trial)

m1231 (1 trial)

m1774 (2 trials)

m3258 (1 trial)

m3541 (1 trial)

m4076 (1 trial)

m5717 (2 trials)

m6495 (2 trials)

m8891 (1 trial)

m9140 (1 trial)

midazolam (versed) (2 trials)

montanide isa51 (1 trial)

MS 201408-0005A (1 trial)

msb0010841 (1 trial)

msb0011359c (2 trials)

msc2363318a (1 trial)

msc-2364447 (1 trial)

msc2490484a (2 trials)

muc1 peptide (1 trial)

omeprazole (prilosec) (1 trial)

pantoprazole (protonix) (1 trial)

rosuvastatin (crestor) (1 trial)

sar405838 (1 trial)

sumatriptan (zecuity) (1 trial)

tamoxifen (nolvadex) (1 trial)

temsirolimus (torisel) (1 trial)

tocilizumab (actemra) (1 trial)

Drugs in Other Trials (4)

Key: Merck Serono (1) Acquired (3)

albendazole (Albenza) (1 trial)

autologous microbiome (1 trial)

ivermectin (stromectol) (1 trial)

linagliptin (tradjenta) (1 trial)

Indications

Approved Indications


 

Dwarfism, Pituitary

Leukemia, Myeloid, Acute

Multiple Sclerosis, Chronic Progressive

Prostatic Neoplasms

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Acute Coronary Syndrome (Phase 3)

Adenocarcinoma (Phase 3)

Alzheimer Disease (Phase 2)

Amenorrhea (Phase 4)

Angina Pectoris (Phase 4)

Angina, Stable (Phase 4)

Anovulation (Phase 3)

Anus Neoplasms (Phase 2)

Arthritis (Phase 3)

Arthritis, Psoriatic (Phase 3)

Arthritis, Rheumatoid (Phase 2)

Autoimmune Diseases (Phase 4)

Autoimmune Diseases of the Nervous System (Phase 4)

Biliary Tract Neoplasms (Phase 3)

Breast Neoplasms (Phase 3)

Cachexia (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cholangiocarcinoma (Phase 3)

Cognitive Dysfunction (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Coronavirus Infections (Phase 2)

Crohn Disease (Phase 2)

Demyelinating Autoimmune Diseases, CNS (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Dwarfism (Phase 4)

Dwarfism, Pituitary (Phase 4)

Dyskinesias (Phase 3)

Endocrine System Diseases (Phase 3)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 2)

Essential Hypertension (Phase 4)

Failure to Thrive (Phase 1)

Fetal Growth Retardation (Phase 3)

Fractures, Stress (Phase 2)

Gallbladder Neoplasms (Phase 3)

Glioblastoma (Phase 3)

Glomerulonephritis, IGA (Phase 2)

Gonadal Dysgenesis (Phase 4)

Head and Neck Neoplasms (Phase 3)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Hematologic Neoplasms (Phase 2)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

HIV Infections (Phase 3)

HIV Wasting Syndrome (Phase 3)

Hyperprolactinemia (Phase 4)

Hypertension (Phase 4)

Hypogonadism (Phase 4)

Hypopituitarism (Phase 3)

Immunologic Deficiency Syndromes (Phase 3)

Infertility (Phase 4)

Insulin Resistance (Phase 2)

Kidney Diseases (Phase 2)

Kidney Neoplasms (Phase 1)

Leiomyosarcoma (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Limb Deformities, Congenital (Phase 2)

Lipodystrophy (Phase 3)

Liver Diseases (Phase 1)

Liver Neoplasms (Phase 2)

Lordosis (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Interstitial (Phase 2)

Lung Neoplasms (Phase 3)

Lupus Erythematosus, Systemic (Phase 3)

Lupus Nephritis (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Mantle-Cell (Phase 2)

Melanoma (Phase 2)

Metabolic Syndrome (Phase 2)

Microsatellite Instability (Phase 2)

Multiple Myeloma (Phase 1)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Myelitis (Phase 4)

Myelitis, Transverse (Phase 4)

Myocardial Ischemia (Phase 4)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 1)

Neoplasms, Second Primary (Phase 2)

Nephritis (Phase 3)

Nervous System Diseases (Phase 4)

Neuritis (Phase 2)

Neuromyelitis Optica (Phase 4)

Optic Neuritis (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Parkinson Disease (Phase 3)

Phenylketonurias (Phase 4)

Pituitary Diseases (Phase 4)

Pneumonia (Phase 2)

Polycystic Ovary Syndrome (Phase 3)

Polyomavirus Infections (Phase 2)

Prostatic Neoplasms (Phase 2)

Psoriasis (Phase 4)

Rectal Neoplasms (Phase 2)

Recurrence (Phase 4)

Renal Insufficiency (Phase 2)

Sarcoma (Phase 2)

Schistosomiasis (Phase 3)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 4)

Short Bowel Syndrome (Phase 4)

Skin Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 3)

Syndrome (Phase 4)

Triple Negative Breast Neoplasms (Phase 2)

Turner Syndrome (Phase 4)

Ulcer (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Vaginal Diseases (Phase 4)

Vaginal Neoplasms (Phase 2)

Vaginosis, Bacterial (Phase 4)

Virus Diseases (Phase 3)

Wasting Syndrome (Phase 3)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 506
  • # of Trial APIs: 216